News related to Keppra (Levetiracetam) and/or conditions it is approved for
Keppra XR Approved for Partial-Onset Seizures
Source: MedicineNet Seizure Specialty [2008.09.16]
Title: Keppra XR Approved for Partial-Onset Seizures
Category: Health News
Created: 9/16/2008 2:00:00 AM
Last Editorial Review: 9/16/2008
Keppra XR(TM) Approved In The U.S. As Add-On To Other Antiepileptic Treatments For People With Partial Onset Seizures
Source: Epilepsy News From Medical News Today [2008.09.15]
UCB announced that the U.S. Food and Drug Administration (FDA) has approved Keppra XR(TM) (levetiracetam extended-release tablets) for use as an add-on to other antiepileptic treatments for people with partial onset seizures who are 16 years of age and older. Keppra XR(TM) is expected to be available in U.S. pharmacies at the end of September 2008. The goal of therapy with antiepileptic drugs (AEDs) is freedom from seizures and minimal side effects.
The First Direct Structural Evidence Of SV2A Has Been Revealed Thanks To Protein Tomography(TM), And Published In BBRC
Source: Epilepsy News From Medical News Today [2008.09.10]
Sidec AB has together with UCB published the first direct structural evidence of the molecular mechanism of the Synaptic Vesicle protein 2A (SV2A) in mouse brain tissue. SV2A is the unique brain-binding site of the second generation anti-epileptic drug levetiracetam (LEV; Keppra(R) is a trademark of UCB). The result shows the first direct structural proof of the "alternating access model" that has been proposed for the MFS class of transporter proteins.
International Team Finds Gene Associated With Epilepsy
Source: Epilepsy News From Medical News Today [2008.11.19]
A University of Iowa-led international research team has found a new gene associated with the brain disorder epilepsy. While the PRICKLE1 gene mutation was specific to a rare form of epilepsy, the study results could help lead to new ideas for overall epilepsy treatment. The findings, which involved nearly two dozen institutions from six different countries, appear in the Nov. 7 issue of the American Journal of Human Genetics.
Falls In Blood Oxygen Levels May Be Key To Sudden Death In Some Epilepsy Patients
Source: Epilepsy News From Medical News Today [2008.11.18]
A new study by researchers at UC Davis Medical Center suggests that the sudden unexplained deaths of some epilepsy patients may be a result of their brains not telling their bodies to breathe during seizures. "Significant drops in blood oxygen levels are more common than we thought in patients with partial seizures," said study senior author Masud Seyal, a professor of neurology at UC Davis Medical Center and director of the UC Davis Comprehensive Epilepsy Program.
Lutheran General Hospital Neurologist Treats Epilepsy With Vagal Nerve Stimulation (VNS) Therapy
Source: Epilepsy News From Medical News Today [2008.11.07]
Daniel Brewer of Palatine has gone from having four to five epileptic seizures a day to a few minor ones in the six months since his surgery for vagal nerve stimulation (VNS) therapy to help control electric signals from his brain. "This has completely changed my life," said the 29-year-old who has had 'every drug known to man' to treat his epilepsy, which he has struggled to control for the past 16 years.
Epilepsy Drug May Prevent, Treat Alzheimer's
Source: MedicineNet Bipolar Disorder Specialty [2008.10.31]
Title: Epilepsy Drug May Prevent, Treat Alzheimer's
Category: Health News
Created: 10/31/2008 2:00:00 AM
Last Editorial Review: 10/31/2008
Alzheimer's Disease Could Be Prevented And Treated By Common Epilepsy Drug
Source: Epilepsy News From Medical News Today [2008.10.28]
The team led by UBC Psychiatry Prof. Weihong Song, who is also the Jack Brown and Family Professor and Chair in Alzheimer's Disease at UBC, found that if Valproic Acid (VPA) is used as a treatment in early stages of AD memory deficit is reversed. The study, published in the Journal of Experimental Medicine, reveals that VPA works by inhibiting the activity of an enzyme that produces a neurotoxic protein called beta Amyloid. In doing so, plaque formation is discontinued.
Epilepsy Foundation Seeking Signatures
Source: Epilepsy News From Medical News Today [2008.10.27]
In 2009 in the USA, a new President, 535 members of Congress and nearly 10,000 state legislators will take office. By signing our petition, you can help us persuade them to support policies that improve the lives of the three million American families affected by epilepsy. More than 3 million Americans have epilepsy (seizures) and 200,000 new cases are diagnosed yearly. For most, there is no cure and many with epilepsy face discrimination and difficulty accessing care.
Epilepsy Phenome/Genome Project - First And Largest Research Study Of Its Kind To Understand What Causes Epilepsy
Source: Epilepsy News From Medical News Today [2008.10.27]
The Epilepsy Phenome/Genome Project (EPGP) consists of a group of researchers, physicians, coordinators, family members, people with epilepsy, advocates, and friends working together unlock the mysteries of epilepsy. EPGP is the first and largest research study of its kind to understand what causes epilepsy, why people respond differently to medications, and why some families have several people with seizures.
Epilepsy: A New Relationship Between Brain Derived Neurotrophic Factor And Inflammatory Signaling
Source: Epilepsy News From Medical News Today [2008.10.23]
In the October 14th edition of Science Signaling researchers at Boston University School of Medicine (BUSM), The Children's Hospital of Philadelphia/University of Pennsylvania School of Medicine and The University of Colorado Denver School of Medicine have shown that the development of epi
VIMPAT (lacosamide), A New Epilepsy Treatment For Adults With Partial Onset Seizures, Launched In The UK
Source: Epilepsy News From Medical News Today [2008.10.14]
Vimpat (lacosamide), a new adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in patients with epilepsy aged 16 years and older, has been launched in the UK. The efficacy of VIMPAT® as adjunctive therapy at recommended doses (200 mg/day, 400 mg/day) was established in 3 multicentre, randomised, placebo-controlled clinical trials with a 12-week maintenance period.
Health Tip: Coping With Epilepsy
Source: MedicineNet Seizure Specialty [2008.10.13]
Title: Health Tip: Coping With Epilepsy
Category: Health News
Created: 10/11/2008 2:00:00 AM
Last Editorial Review: 10/13/2008
New Data Show Efficacy Of Zebinix(TM) In The Treatment Of Epilepsy
Source: Epilepsy News From Medical News Today [2008.09.25]
Novel Treatment Also Demonstrated Significant Improvement in Quality of Life and Reduction in Depressive Symptoms Positive data from three phase III studies presented at the 8th European Congress of Epileptology, Berlin, Germany, demonstrated that Zebinix(TM) (1)
IBE And UCB Launch New Journalism Award To Improve Understanding Of Epilepsy Around The World
Source: Epilepsy News From Medical News Today [2008.09.23]
The International Bureau for Epilepsy (IBE) in partnership with UCB, launched a new Journalism Award. The 'Excellence in Epilepsy' Journalism Award invites journalists from around the world to submit stimulating, informed and compelling news and feature stories on epilepsy. The Award is part of a global initiative to increase awareness and understanding of a condition that affects 50 million people, but still remains widely misunderstood.
Epilepsy In Later Life Conference, Scotland
Source: Epilepsy News From Medical News Today [2008.09.17]
Guiding good practice for epilepsy in later life Older people who develop epilepsy will have better diagnosis and treatment thanks to a new draft guideline. This guidance is being further developed by delegates attending Epilepsy Scotland's conference, today, in the Royal College of Physicians, Edinburgh.
New Epilepsy Campaign Promotes Healthy Mums And Babies, UK
Source: Epilepsy News From Medical News Today [2008.09.11]
Every year, around four women with epilepsy die during pregnancy or giving birth, meaning they face a seven times greater risk than women without epilepsy, warns national charity Epilepsy Action. It is this gap which has prompted the charity to launch its Mothers in mind: healthy births campaign during National Pregnancy Health Month (September). The campaign will work towards giving more mums with epilepsy and their babies a happy and healthy future.
Dangerous Side-Effects Of Epilepsy Drugs Reduced In New Research
Source: Epilepsy News From Medical News Today [2008.09.08]
A breakthrough method has been found to reduce the dangerous side-effects of a medicine that successfully tackles epilepsy, according to research released at the British Pharmaceutical Conference (BPC) in Manchester. Epilepsy is an incurable condition which causes people to suffer repeated seizures caused by a burst of abnormal electrical activity in the brain. It affects about one in 30 people in the UK.
3T MRI Leads To Better Diagnosis For Focal Epilepsy
Source: Epilepsy News From Medical News Today [2008.09.06]
3T MRI is better at detecting and characterizing structural brain abnormalities in patients with focal epilepsy than 1.5T MRI, leading to a better diagnosis and safer treatment of patients, according to a recent study conducted at the Oregon Health and Science University in Portland, OR. "Patients with focal epilepsy have recurrent seizures that result from a specific area of their brain, usually due to a structural brain abnormality," said Bronwyn E.
Vimpat(R) Approved In Europe - First New Epilepsy Treatment For Partial-Onset Seizures In Three Years
Source: Epilepsy News From Medical News Today [2008.09.03]
UCB announced that the European Commission (EC) has approved Vimpat® (lacosamide) as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in patients with epilepsy aged 16 years and older. Vimpat® is the first new antiepileptic drug (AED) for partial-onset seizures in three years and offers a new treatment option for European patients living with uncontrolled partial-onset epilepsy.
Pediatric Epilepsy Surgery
Source: MedicineNet Cerebral Palsy Specialty [2008.08.26]
Title: Pediatric Epilepsy Surgery
Category: Procedures and Tests
Created: 1/18/2001
Last Editorial Review: 8/26/2008
FDA Panel: No Warning on Epilepsy Drugs
Source: MedicineNet carbamazepine Specialty [2008.07.11]
Title: FDA Panel: No Warning on Epilepsy Drugs
Category: Health News
Created: 7/11/2008
Last Editorial Review: 7/11/2008
Epilepsy (Seizure Disorder)
Source: MedicineNet Celiac Disease Specialty [2008.05.09]
Title: Epilepsy (Seizure Disorder)
Category: Diseases and Conditions
Created: 12/31/1997
Last Editorial Review: 5/9/2008
Epilepsy Drug Linked to Bone Loss
Source: MedicineNet carbamazepine Specialty [2008.04.29]
Title: Epilepsy Drug Linked to Bone Loss
Category: Health News
Created: 4/29/2008 2:00:00 AM
Last Editorial Review: 4/29/2008
Epilepsy Drug Doesn't Prevent Migraines
Source: MedicineNet carbamazepine Specialty [2008.02.12]
Title: Epilepsy Drug Doesn't Prevent Migraines
Category: Health News
Created: 2/12/2008 2:00:00 AM
Last Editorial Review: 2/12/2008
Suicide Risk From 11 Epilepsy Drugs
Source: MedicineNet carbamazepine Specialty [2008.02.01]
Title: Suicide Risk From 11 Epilepsy Drugs
Category: Health News
Created: 2/1/2008
Last Editorial Review: 2/1/2008
Calm in the Storm: A Child's Life with Epilepsy
Source: MedicineNet Pediatric Epilepsy Surgery Specialty [2006.12.01]
Title: Calm in the Storm: A Child's Life with Epilepsy
Category: Health Tips
Created: 12/1/2006
Last Editorial Review: 12/1/2006
Surgical Options for Epilepsy
Source: MedicineNet Pediatric Epilepsy Surgery Specialty [2005.01.31]
Title: Surgical Options for Epilepsy
Category: Procedures and Tests
Created: 1/31/2005 8:06:00 AM
Last Editorial Review: 1/31/2005 8:06:28 AM
UCB's Vimpat® Approved By U.S. FDA As Adjunctive Therapy For Partial Onset Seizures In Adults
Source: Epilepsy News From Medical News Today [2008.10.29]
UCB announced today that the U.S. Food and Drug Administration (FDA) has approved Vimpat® (lacosamide), a new antiepileptic drug (AED). Vimpat® is for use as an add-on therapy for the treatment of partial-onset seizures in people with epilepsy who are 17 years and older. "Having a new antiepileptic drug option may offer adults with partial onset seizures the chance to obtain seizure control.
Epileptic Spasms In Infants May Be Eliminated By Diet
Source: Epilepsy News From Medical News Today [2008.09.10]
Infantile spasms are a severe and potentially devastating epilepsy condition affecting children aged typically 4-8 months. In a new study appearing in Epilepsia, researchers have found that the ketogenic diet, a high fat, low carbohydrate diet more traditionally used for intractable childhood epilepsy, is an effective treatment for this condition before using drugs. The study is the first description of the ketogenic diet as a first-line therapy for infantile spasms.
High Cholesterol Levels Drop Naturally In Children On High-Fat Anti-Seizure Diet, Hopkins Study Show
Source: Epilepsy News From Medical News Today [2008.08.28]
Elevated cholesterol levels return to normal or near normal levels over time in four out of 10 children with uncontrollable epilepsy treated with the high-fat ketogenic diet, according to results of a Johns Hopkins Children's Center study reported in the Journal of Child Neurology. The study appears online ahead of print here.
High Cholesterol Levels Drop Naturally In Children On High-Fat Antiseizure Diet
Source: Epilepsy News From Medical News Today [2008.08.28]
Elevated cholesterol levels return to normal or near normal levels over time in four out of 10 children with uncontrollable epilepsy treated with the high-fat ketogenic diet, according to results of a Johns Hopkins Children's Center study reported in the Journal of Child Neurology. The study appears online ahead of print here.
|
